Biopharmaceutical company Incyte Corporation (NASDAQ: INCY) will be announcing earnings results this Tuesday morning. Here’s what to expect.

Incyte beat analysts’ revenue expectations by 6.4% last quarter, reporting revenues of $1.05 billion, up 19.5% year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ EPS estimates.

Is Incyte a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Incyte’s revenue to grow 10.2% year on year to $1.15 billion, in line with the 9.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.47 per share.

Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 6 downward revisions over the last 30 days (we track 18 analysts). Incyte has missed Wall Street’s revenue estimates twice over the last two years.

With Incyte being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. Incyte is up 4% during the same time and is heading into earnings with an average analyst price target of $75.41 (compared to the current share price of $70.81).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.